Stock Forecast

  iCAD, Inc. ( ICAD) Stock. Should you Buy or Sell?    $ 2.79

0.05 (1.76 %)

iCAD, Inc. Analysis

Updated on 10-09-2022
Symbol ICAD
Price $2.79
Beta 1.075
Volume Avg. $147.03 thousand
Market Cap $70.68 M
52 Week Range $2.59 - $12.6

iCAD, Inc. opened the day at $2.79 which is +'1.76 % on yesterday's close. iCAD, Inc. has a 52 week high of $12.6 and 52 week low of $2.59, which is a difference of $10.01. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $70.68 M and total net profit is $33638000 which means the company is trading at 2.10 times profit to market capitalization. Theoretically, if you were to buy iCAD, Inc. for $70.68 M, it would take 15 years to get your money back. iCAD, Inc. are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


iCAD, Inc. Stock Forecast - Is iCAD, Inc. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value

PE Ratio -5.406
Dividend Yiel 0.000
Net Profit Margin -0.402

Valuing iCAD, Inc.

Price Book Value Ratio 1.713 Price To Book Ratio 1.713
Price To Sales Ratio 2.175 Price Earnings Ratio -5.406

How liquid is iCAD, Inc.

Current Ratio 3.189
Quick Ratio 2.629


Debt Ratio 0.298 Debt Equity Ratio 0.424
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000

Latest news about iCAD, Inc.

After Plunging 29.6% in 4 Weeks, Here's Why the Trend Might Reverse for Icad (ICAD)

Icad (ICAD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Date : 19/08/2022

iCAD, Inc. (ICAD) CEO Stacey Stevens on Q2 2022 Results - Earnings Call Transcript

iCAD, Inc. (NASDAQ:ICAD ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Tony Takazawa - Director, Investor Relations Stacey Stevens - President and Chief Executive Officer Steve Sarno - Interim Chief Financial Officer Conference Call Participants Per Ostlund - Craig Hallum Capital Group Sam Eiber - BTIG Charlie Montang - Lake Street Capital Francois Brisebois - Oppenheimer Yale Jen - Laidlaw and Company Operator Good afternoon, ladies and gentlemen. And welcome to the iCAD, Inc. Second Quarter 2022 Earnings Call.

Date : 10/08/2022

Icad (ICAD) Reports Q2 Loss, Lags Revenue Estimates

Icad (ICAD) delivered earnings and revenue surprises of 0% and 15.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Date : 10/08/2022

iCAD to Present at the JMP Securities Life Sciences Conference on June 15-16, 2022

NASHUA, N.H., June 06, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the JMP Securities Life Sciences Conference, taking place June 15-16, 2022 in New York City.

Date : 06/06/2022

5 Growth Stocks to Buy Now

EPS estimates are generally a strong indication of future growth. That's just one part of finding reliable growth stocks.

Date : 27/05/2022

About iCAD, Inc.

CEO : Mr. Michael Klein
Sector : Healthcare
Industry : Medical Devices

Website :

Exchange : NASDAQ Capital Market

Description :

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

My Newsletter

Sign Up For Updates & Newsletters